Clinical trials: Type1 Diabetes
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia…
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1
- Trial name
- NCT01781975
- Testing
- Imatinib Mesylate
- Where
- 9 sites in United States, Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Type 1 Diabetes Mellitus
Detemir: Role in Type 1 Diabetes
Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart).
- Trial name
- NCT00564395
- Testing
- Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Montefiore Medical Center
Diabetes Mellitus, Type 1
STOP-T1D Low-Dose (ATG)
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
- Trial name
- TN28 (NCT04291703)
- Testing
- Antithymocyte Globulin
- Where
- 22 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
Immune Profile in Subjects With New Onset Type 1 Diabetes
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed…
- Trial name
- NCT02801942
- Testing
- Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, Peripheral blood collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
Sitagliptin Dose Determination Study
There are many recent advances in insulin treatment of type 1 diabetes, however after a meal sugars are always a concern. There is a drug sitagliptin (Januvia) which is FDA approved to treat people with type 2 diabetes which…
- Trial name
- NCT01530178
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Albert Einstein College of Medicine
Type 1 Diabetes Mellitus
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin.
- Trial name
- DIA-AID2 (NCT01103284)
- Testing
- DiaPep277
- Where
- 75 sites in United States, Austria and 12 more
- Volunteers
- 475 people
- Sponsor
- Andromeda Biotech Ltd.
Type 1 Diabetes Mellitus
Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp
An early feasibility study that will test the efficacy of the Tandem t:slim X2 with Control-IQ and Dexcom Continuous Glucose System G6 in a winter/ski camp environment.
- Trial name
- NCT03369067
- Testing
- Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Virginia
Peripheral Neuropathy, Type 1 Diabetes
Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy
This 12 week study will examine the effects of daily Salsalate treatment on markers of neuropathic pain and intra-epidermal nerve fiber density.
- Trial name
- SALP (NCT01480297)
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Diabetes Mellitus, Type 1
Feasibility Trial Testing the Bionic Pancreas With ZP4207
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus.
- Trial name
- dasiglucagon (NCT02971228)
- Testing
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes
Diabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.
- Trial name
- DIRECT (NCT00252733)
- Testing
- candesartan cilexetil
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 5,238 people
- Sponsor
- AstraZeneca
Hypoglycemia Unawareness, Type 1 Diabetes
Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs.
- Trial name
- NCT02700048
- Testing
- intra-nasal naloxone, Intra-nasal saline
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Type 1 Diabetes, Peripheral Neuropathy
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Diabetic neuropathy (DN) is the most common chronic complication of diabetes, affecting up to50% of individuals with type 1 diabetes (T1DM).
- Trial name
- TINSAL-T1DN (NCT02936843)
- Testing
- Salsalate
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Michigan
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).
- Trial name
- inTandem3 (NCT02531035)
- Testing
- Sotagliflozin
- Where
- 135 sites in United States, Argentina and 17 more
- Volunteers
- 1,405 people
- Sponsor
- Lexicon Pharmaceuticals
Type 1 Diabetes, Hypoglycemia
CGM Use in Poorly Controlled Youth With Type 1 Diabetes
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in high risk, poorly controlled pediatric Type 1 diabetes patients increases uptake of personal CGM use, and…
- Conditions
- Type 1 Diabetes, Hypoglycemia, High Blood Sugar
- Trial name
- IMPaCT (NCT04721145)
- Testing
- Dexcom G6 Continuous Glucose Monitor
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes Mellitus
Fuzzy Logic Automated Insulin Regulation
Adolescents and young adults with type 1 diabetes often have a difficult time achieving good glucose control, which is so important in reducing the risk for diabetes complications.
- Trial name
- FLAIR (NCT03040414)
- Testing
- MedtronicMinimed 670G 3.0 hybrid closed loop system, Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 126 people
- Sponsor
- HealthPartners Institute
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to…
- Trial name
- Onset® 5 (NCT02825251)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 92 sites in United States, Belgium and 7 more
- Volunteers
- 472 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Preservation of Insulin Secretion
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Canakinumab is a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody (IgG-1 class). Canakinumab is designed to bind to human IL-1β and to functionally neutralize the bioactivity of this pro-inflammatory cytokine.
- Conditions
- Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
- Trial name
- TN14 (NCT00947427)
- Testing
- canakinumab (anti IL-1beta)
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes
The Pediatric Artificial Pancreas Automated Initialization Trial
The goal of this clinical trial is to obtain safety data and exploratory glycemic control data from use of an at-home closed loop control (CLC) system (t:slim X2 with Control-IQ Technology) with periodic parameter adjustments…
- Trial name
- PEDAP-AI (NCT06017089)
- Testing
- AI-based Advisor system
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Marc Breton
Diabetes Mellitus, Type 1
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes.
- Trial name
- NCT01600950
- Testing
- LY2963016, Lantus
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Liraglutide in Type 1 Diabetes
The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes.
- Trial name
- 1966 (NCT01722240)
- Testing
- Liraglutide 1.8mg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University at Buffalo